Jeffrey G. Park
Known title: DirectorCIK: 0001406618
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PIII appoints new Chief Clinical Officer. P3 Health Partners announced the appointment of a new Chief Clinical Officer. The executive will oversee clinical operations and strategy for the company. This addition brings additional expertise as the firm pursues its growth plans. The stock is currently trading with a low RSI and near its recent support level.
Transaction History
| PGNY | ▲ Buy | Grant | 7,924 | $0 | 5/21/2026 | View on chart |
| PIII | ▲ Buy | Grant | 2,000 | $0 | 8/6/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 9,364 | $0 | 5/22/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 6,176 | $0 | 5/23/2024 | View on chart |
| PIII | ▲ Buy | Grant | 216,561 | $0 | 10/23/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 4,385 | $0 | 5/24/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 3,480 | $0 | 10/24/2022 | View on chart |
| PGNY | ▲ Buy | Grant | 2,652 | $0 | 10/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace
Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.